BRCA1 and familial pancreatic carcinoma: While inhibitors of PARP have been approved for BRCA-mutated cancers, exploiting synthetic lethality in DNA repair pathways [11, 12], only 5-10% of pancreatic cancer patients possess BRCA1 or BRCA2 mutations [1, 13], limiting the applicability of PARP inhibitors in pancreatic cancer treatment.